The

Dermatology CRO

Built for Sponsors

Run your trial with faster execution and higher quality

Why the Vial Dermatology CRO?

Streamlined trial startup, more predictable patient recruitment, and higher quality data.

Vial is able to leverage the abilities and resources within our site network in conjunction with our turnkey CRO capabilities, to provide our sponsors with a fully integrated service offering.

Site Network

Trials Powered by Vial’s
Fully Integrated Clinic Network

Sites
  • 80M+ Population

    within 50 miles of Vial sites

  • 35+

    Top Recruiting Sites

We have thoughtfully built our network to incorporate research experienced dermatologists who not only have a passion for new dermatology therapies, but also access to a wide range of patients.

We have thoughtfully built our network to incorporate research experienced dermatologists who not only have a passion for new dermatology therapies, but also access to a wide range of patients.

We embed our own clinical research coordinators and support staff to work side by side with highly trained PIs and Sub-Is to facilitate patient visits and deploy Vial’s optimized operational model consistently across all sites.

We embed our own clinical research coordinators and support staff to work side by side with highly trained PIs and Sub-Is to facilitate patient visits and deploy Vial’s optimized operational model consistently across all sites.

CRO Services

We Support Our Client’s Development Programs with the Following Services

vial cro
vial cro

Upon site activation, Vial’s recruitment engine goes to work, funneling patients in close geographic proximity to their site for screening and enrollment.

Lightning Fast Start-up
and Consolidated Site Activation

vial cro
vial cro

Our Dermatology CRO Executive Team

Our Dermatology CRO Executive
Team has over 100 years combined experience managing dermatology studies in all phases
of development

Our experienced CRO executive team works closely with our expert site operations team to continuously review execution strategies, closely monitor patient recruitment efforts, and mitigate key study risks.

More than 25 years in clinical research industry – 18 of those years holding strategic roles in a Dermatology CRO setting.

More than 20 years as a leading PI in Dermatology, has been the PI for 200+ Dermatology studies across indications.

More than 20 years experience in the clinical research industry – holding site coordinator, monitoring and project management roles.

More than 20 years in healthcare sector, on both sponsor and CRO side of equation.

Waldman Professor and Chairman of the Kimberly and Eric J. Waldman Department of and Chairman of the Department of Dermatology at the Mount Sinai Hospital in New York City

Dr. Lebwohl is chairman emeritus of the Medical Board of the National Psoriasis Foundation. He is the founding editor of Psoriasis Forum and the Journal of Psoriasis and Psoriatic Arthritis. He has been on the editorial board of the Journal of the American Academy of Dermatology and the Journal of Skin Cancer. He is editor of the Dermatology Section of Scientific American Medicine and co-Editor-in-Chief of Skin, the Journal of Cutaneous Medicine. He has authored or co-authored over 600 publications including articles, chapters and abstracts. Dr. Lebwohl is actively involved in clinical trials of many new dermatologic treatments.

Lebwohl

Senior physician of Pariser Dermatology Specialist and Principal Investigator

Dr. Pariser is distinguished for his world-renowned expertise on psoriasis, hyperhidrosis and photodynamic therapy, a treatment for early skin cancers and pre-cancers. Throughout the span of his career, his research has led to the publication of over 300 scientific publications and 4 textbooks in medical literature.

Pariser

Associate Professor in the Department of Dermatology and Department of Medicine, Division of Rheumatology at Harvard Medical School

Dr. Merola is triple board certified in Dermatology, Internal Medicine, and Rheumatology. Dr. Merola is on the Medical Board of the National Psoriasis Foundation, the Board of the International Dermatology Outcome Measures Group, Steering Committee Member for GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis), the Board of the Lupus Foundation of America and is on the Board and Founding President of the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN). Dr. Merola is also the president-elect of the Medical Dermatology Society. He is an active PI in several Psoriasis, Atopic Dermatitis and other leading skin indications.

Merola

Our experienced CRO executive team works closely with our expert site operations team to continuously review execution strategies, closely monitor patient recruitment efforts, and mitigate key study risks.

Case Study

Recruitment Timelines Met. Guaranteed.

Trial Expectations
Goal # of Patients per site:
10 patients / site
Goal time:
>4 months
Vial Site Actuals
Vial # of Patients per site:
~35 patients / site
Recruitment time:
~1-2 months

In a Phase 3 Hyperhidrosis study,
all 3 Vial sites significantly beat the enrollment goals in a reduced time frame.

Our recruitment timelines are so predictably fast, we stand by our guarantees.

In a Phase 3 Hyperhidrosis study,
all 3 Vial sites significantly beat the enrollment goals in a reduced time frame.

Our recruitment timelines are so predictably fast, we stand by our guarantees.

Deep clinic operation integration drives higher quality data for Sponsors.

Vial's is the first CRO powered by a clinic network. Learn more about our higher quality and faster execution.

Learn more about the Vial Site Network

Lightning Fast Start-up and Consolidated Site Activation

vial cro
dermatology cro

Standardized Quality Across Our PIs

dermatology cro

Highly Experienced CRCs

vial cro